A detailed history of Morse Asset Management, Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Morse Asset Management, Inc holds 4,819 shares of REGN stock, worth $3.65 Million. This represents 1.09% of its overall portfolio holdings.

Number of Shares
4,819
Previous 4,764 1.15%
Holding current value
$3.65 Million
Previous $5.01 Million 1.18%
% of portfolio
1.09%
Previous 1.21%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1024.09 - $1201.76 $4.94 Million - $5.79 Million
4,819 New
4,819 $5.07 Million
Q2 2024

Aug 14, 2024

BUY
$883.2 - $1071.19 $158,976 - $192,814
180 Added 3.93%
4,764 $5.01 Million
Q1 2024

May 15, 2024

BUY
$902.69 - $993.35 $42,426 - $46,687
47 Added 1.04%
4,584 $4.41 Million
Q4 2023

Feb 15, 2024

BUY
$775.18 - $881.7 $333,327 - $379,131
430 Added 10.47%
4,537 $3.99 Million
Q3 2023

Nov 13, 2023

BUY
$692.45 - $844.37 $126,718 - $154,519
183 Added 4.66%
4,107 $3.38 Million
Q2 2023

Aug 14, 2023

BUY
$700.03 - $830.35 $112,704 - $133,686
161 Added 4.28%
3,924 $2.82 Million
Q1 2023

May 03, 2023

BUY
$680.49 - $826.97 $51,036 - $62,022
75 Added 2.03%
3,763 $3.09 Million
Q4 2022

Feb 08, 2023

BUY
$705.89 - $766.39 $5,647 - $6,131
8 Added 0.22%
3,688 $2.66 Million
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $73,468 - $92,712
-128 Reduced 3.36%
3,680 $2.54 Million
Q2 2022

Aug 11, 2022

BUY
$548.35 - $738.84 $279,110 - $376,069
509 Added 15.43%
3,808 $2.25 Million
Q1 2022

May 12, 2022

BUY
$595.12 - $698.43 $190,438 - $223,497
320 Added 10.74%
3,299 $2.3 Million
Q4 2021

Feb 14, 2022

SELL
$543.48 - $670.97 $62,500 - $77,161
-115 Reduced 3.72%
2,979 $1.88 Million
Q3 2021

Nov 09, 2021

BUY
$574.03 - $680.96 $989,627 - $1.17 Million
1,724 Added 125.84%
3,094 $1.87 Million
Q2 2021

Aug 13, 2021

BUY
$472.8 - $558.54 $309,211 - $365,285
654 Added 91.34%
1,370 $765,000
Q1 2021

May 13, 2021

BUY
$446.73 - $548.2 $11,168 - $13,705
25 Added 3.62%
716 $339,000
Q4 2020

Feb 11, 2021

SELL
$478.3 - $607.98 $45,438 - $57,758
-95 Reduced 12.09%
691 $334,000
Q2 2020

Aug 14, 2020

BUY
$493.32 - $643.92 $49,332 - $64,391
100 Added 14.58%
786 $490,000
Q1 2020

May 01, 2020

BUY
$336.18 - $494.43 $230,619 - $339,178
686 New
686 $335,000
Q3 2019

Nov 05, 2019

SELL
$273.46 - $318.39 $1.49 Million - $1.73 Million
-5,442 Closed
0 $0
Q2 2019

Aug 01, 2019

SELL
$299.6 - $414.82 $1.12 Million - $1.55 Million
-3,748 Reduced 40.78%
5,442 $1.7 Million
Q1 2019

May 02, 2019

SELL
$372.08 - $439.57 $55,067 - $65,056
-148 Reduced 1.58%
9,190 $3.77 Million
Q4 2018

Feb 13, 2019

BUY
$335.82 - $403.04 $52,387 - $62,874
156 Added 1.7%
9,338 $3.49 Million
Q3 2018

Nov 01, 2018

BUY
$351.14 - $408.51 $1.1 Million - $1.28 Million
3,127 Added 51.64%
9,182 $3.71 Million
Q2 2018

Aug 15, 2018

SELL
$284.6 - $344.99 $583,430 - $707,229
-2,050 Reduced 25.29%
6,055 $2.09 Million
Q1 2018

May 02, 2018

BUY
$315.82 - $393.78 $9,474 - $11,813
30 Added 0.37%
8,105 $2.79 Million
Q4 2017

Jan 29, 2018

SELL
$358.63 - $469.95 $576,677 - $755,679
-1,608 Reduced 16.61%
8,075 $3.04 Million
Q3 2017

Oct 31, 2017

BUY
$431.38 - $504.0 $4.18 Million - $4.88 Million
9,683
9,683 $4.33 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Morse Asset Management, Inc Portfolio

Follow Morse Asset Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morse Asset Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Morse Asset Management, Inc with notifications on news.